SOLESENCE, INC. — Form 8-K
Filed July 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Solesence LLC (Sol sence) settled a dispute with Refy Beauty Ltd dated 6 July 2026 arising from a Contract Manufacturing Agreement dated 3 June 2024. Solesence will pay Refy £700,000 total: £350,000 in six monthly instalments of £58,333.33 (Aug 2026–Jan 2027), plus £350,000 either as credit toward new SPF product contracts during a 6-month exclusivity period, or as additional monthly payments (Feb–Jul 2027) if no new contract is signed. The settlement includes mutual release from all prior claims, a 6-month exclusivity period for SPF product negotiations in good faith, and confidentiality provisions. Payment default triggers acceleration of remaining instalments plus 6% annual interest above Bank of England base rate.
Why this rating
Settlement outlay of £700K (≈$938K at stated 1.34 rate) is ~3.4% of Solesence's $27.3M market cap—material but not catastrophic. Loss of prior manufacturing relationship, good-faith negotiation burden, and contingent payment obligation are operationally significant; exclusivity restricts Refy's sourcing flexibility. Dispute resolution removes litigation risk but signals prior contract problems.
See more from July 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.